

KWAR 23

Cat. No.:	HY-P99175
CAS No.:	2243227-60-1
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	<p>KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research^[1].</p>									
In Vitro	<p>KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage^[1]. KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human macrophages and lymphoma cells</td> </tr> <tr> <td>Concentration:</td> <td>0-1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>4 h</td> </tr> <tr> <td>Result:</td> <td>Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.</td> </tr> </table>		Cell Line:	Human macrophages and lymphoma cells	Concentration:	0-1 μ M	Incubation Time:	4 h	Result:	Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.
Cell Line:	Human macrophages and lymphoma cells									
Concentration:	0-1 μ M									
Incubation Time:	4 h									
Result:	Showed human macrophages and neutrophils killing tumor cells following treatment with KWAR23.									
In Vivo	<p>KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model^[1]. KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>SIRPA knock-in mouse model injected with Burkitt's lymphoma cells^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; 10 mg/kg; every other day; 21 d</td> </tr> <tr> <td>Result:</td> <td>Led to strong inhibition of tumor growth when combined with Rituximab.</td> </tr> </table>		Animal Model:	SIRPA knock-in mouse model injected with Burkitt's lymphoma cells ^[1]	Dosage:	10 mg/kg	Administration:	Intraperitoneal injection; 10 mg/kg; every other day; 21 d	Result:	Led to strong inhibition of tumor growth when combined with Rituximab.
Animal Model:	SIRPA knock-in mouse model injected with Burkitt's lymphoma cells ^[1]									
Dosage:	10 mg/kg									
Administration:	Intraperitoneal injection; 10 mg/kg; every other day; 21 d									
Result:	Led to strong inhibition of tumor growth when combined with Rituximab.									

REFERENCES

[1]. Ring NG, et al. Anti-SIRP α antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA